Racura OncologyASX:RAC -0.90%31 9-Day RSI is 31.18 as of Jul. 01, 2026. GuruFocus rates ASX:RAC with a GF Score™ of 31/100. Among 1,422 Biotechnology companies, Racura Oncology ranks better than 87.06% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-01), Racura Oncology's 9-Day RSI is 31.18.
The industry rank for Racura Oncology's 9-Day RSI or its related term are showing as below:
ASX:RAC's 9-Day RSI is ranked better than 87.06% of 1422
companies
in the Biotechnology industry
Industry Median: 49.72
vs ASX:RAC: 31.18
Racura Oncology (ASX:RAC) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Racura Oncology 9-Day RSI Related Terms
ASX:RAC vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Racura Oncology's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Racura Oncology 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Racura Oncology's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Racura Oncology's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Racura Oncology (ASX:RAC) has a 9-Day RSI of 31.18 as of Jul. 01, 2026. According to the industry distribution chart, Racura Oncology ranks #184 out of 1422 companies in the Biotechnology industry, placing it in the top 12.9%.
Is Racura Oncology's 9-Day RSI too high?
Racura Oncology's current 9-Day RSI is 31.18. The Biotechnology industry median 9-Day RSI is 49.72. Racura Oncology's value of 31.18 is 37.3% below this industry median. Based on the distribution chart, Racura Oncology ranks #184 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #184 out of 1422 companies for 9-Day RSI. This places Racura Oncology in the top 13% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 49.72. Racura Oncology's value of 31.18 is 37.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.72, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Racura Oncology's current 9-Day RSI of 31.18 is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current 9-Day RSI is 31.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current 9-Day RSI of 31.18. The current 9-Day RSI is 31.18 and 37.3% below the Biotechnology industry median of 49.72. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current 9-Day RSI is 31.18 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score
Get the complete analysis for ASX:RAC
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAC has been successfully added to your 